Isoquinoline Alkaloid · Pharmacognosy

Berberine

An isoquinoline alkaloid extracted from Berberis vulgaris, Hydrastis canadensis and related species — whose AMPK-activating, PCSK9-inhibiting and gut microbiota-modulating pharmacology places it among the most clinically evidenced non-pharmaceutical metabolic compounds, with glycaemic efficacy comparable to metformin in randomised controlled trials.

30+ Primary Refs
−2.0% HbA1c (RCT)
7 Mechanisms
Root Parts Used
Updated
Standard Dose 500 mg × 2–3/day
Primary Sources NCBI PubMed · Cochrane
Pregnancy Contraindicated
Evidence Grade A–B · Multiple RCTs · Meta-Analyses Available

Biological Overview

Berberine is an isoquinoline alkaloid with one of the broadest metabolic evidence bases of any non-pharmaceutical compound. Its pharmacological spectrum spans antidiabetic, lipid-lowering, anti-inflammatory, antimicrobial, gut-modulating and anti-obesity activity — mediated through AMPK activation, PCSK9 inhibition, gut microbiota remodelling and mitochondrial complex I inhibition, the same primary target as metformin. A 2008 RCT demonstrated HbA1c reduction comparable to the leading antidiabetic pharmaceutical.

ClassificationIsoquinoline alkaloid
Primary TargetsAMPK · PCSK9 · NF-κB
Bioavailability~1–5% (HCl) — gut-active
Strongest EvidenceGlucose · LDL · PCOS
Supplement Classification

Overview & Classification

IUPAC Name
5,6-dihydro-9,10-dimethoxy-1,3-dioxolo[4,5-g]isoquinolinium
CAS Number
2086-83-1 (HCl: 633-65-8)
Classification
Isoquinoline alkaloid (quaternary ammonium)
Common Forms
Berberine HCl · Phytosome · Dihydroberberine
Characteristic Colour
Bright yellow
Primary Clinical Use
Blood glucose · LDL cholesterol · PCOS
Regulatory Status
Dietary supplement (not approved as drug)
Pregnancy
Contraindicated
Botanical Origin

Plant Sources

Berberine occurs naturally in multiple plant genera. Commercial supplements are extracted from roots, stems and bark — most commonly from Berberis vulgaris.

Primary Berberine-Containing Plants
Berberis vulgaris (Barberry) Most common commercial source · Roots and stem bark · Berberidaceae family · Used in European and Middle Eastern folk medicine for centuries
Primary source
Hydrastis canadensis (Goldenseal) North American species · Root extract · High berberine concentration · Traditionally used by Indigenous North American peoples
High yield
Mahonia aquifolium (Oregon Grape) Pacific Northwest species · Root extract · Traditional antibacterial and digestive use · Also used topically for skin conditions
Commercial
Coptis chinensis (Chinese Goldthread / Huanglian) Primary Traditional Chinese Medicine source · Rhizome extract · Documented use in TCM for diabetes-like symptoms predating modern clinical trials
TCM source
Berberis aristata (Indian Barberry / Daru Haridra) Ayurvedic source · Root and stem bark · Documented in Charaka Samhita · Used in Unani and Ayurvedic medicine for metabolic and hepatic conditions
Ayurvedic

Berberine shares structural and pharmacological territory with alkaloids in several other plants on this site. See the turmeric guide and nigella sativa guide for overlapping metabolic pharmacology.

Phytochemistry

Active Compounds & Bioavailability

All dosage data on this page references berberine HCl — the form used in all cited clinical trials. Enhanced-bioavailability forms may allow lower doses but lack equivalent long-term evidence.

Berberine HCl — Pharmacokinetics
Oral bioavailability~1–5% in standard HCl form
Why low BA matters lessMost activity occurs in intestinal lumen — gut microbiota modulation and local enzyme inhibition occur at high local concentrations without requiring systemic absorption
Peak plasma (Tmax)~1–2 hours post-ingestion
Half-life~4–5 hours — divided dosing maintains stable plasma concentrations
Effect of foodSlows gastric transit, improves intestinal exposure and significantly reduces GI adverse effects — always required
Forms Comparison
Berberine HClStandard form · Reference for all clinical trial dosing · Best evidence base · Most widely available
Reference
Berberine phytosomeComplexed with phosphatidylcholine · ~3× higher absorption vs HCl · Limited RCT data
Enhanced
Dihydroberberine (DHB)Reduced form · ~5× higher absorption · Converts back to berberine post-absorption · Emerging research only
Novel
Nanoparticle formsResearch stage only · Not commercially available in standardised validated form
Experimental
Clinical Protocols

Dosage & Protocols

Dosage protocols across clinical trials are highly consistent. The standard evidence-based protocol is 500 mg berberine HCl taken 2–3 times daily with meals.

Protocol Dose Timing Total/Day Primary Use
Standard metabolic 500 mg × 3 With each meal 1,500 mg Blood glucose, HbA1c, lipids — protocol used in most RCTs [1],[2]
Lipid-focused 500 mg × 2 With main meals 1,000 mg LDL/TG reduction; lower dose remains clinically active for lipids [12]
PCOS protocol 500 mg × 3 With meals 1,500 mg Dose matched to metformin comparator in Wei et al. 2012 RCT [8]
Tolerability titration 500 mg × 2 → 3 With meals 1,000–1,500 mg GI-sensitive users; start twice daily for 1–2 weeks before increasing
Maximum studied 500 mg × 4 With meals 2,000 mg No clear benefit vs 1,500 mg; higher GI adverse event rate; not routinely recommended

⊗ Critical — Always take with food

Food slows gastric transit, prolonging berberine’s contact time with the intestinal mucosa and improving net activity despite low systemic bioavailability. It also significantly reduces nausea, cramping and diarrhoea. Fasted dosing is not how trials were conducted and is not recommended.

Cycling: Some clinicians recommend 8–12 weeks on, 4 weeks off. Evidence for tolerance development is limited — most trials up to 24 months found stable efficacy without cycling. This practice remains clinician preference rather than evidence mandate.

Pharmacological Properties

Whole-compound biological activities referenced to primary literature

7 Mechanisms Multiple RCTs Meta-Analyses 30+ References
🩸

Antidiabetic — Blood Glucose Lowering

Reduces fasting and postprandial glucose via AMPK activation and hepatic gluconeogenesis inhibition. [1],[2] Meta-analysis of 14 RCTs (n=1,068): mean fasting glucose −1.03 mmol/L, HbA1c −0.71% vs placebo. [3] Comparable to metformin in landmark 2008 head-to-head RCT. [1]

❤️

Lipid Lowering — LDL & Triglycerides

Reduces total cholesterol, LDL-C and triglycerides via PCSK9 inhibition and AMPK-driven fatty acid oxidation. [4],[5] Meta-analysis of 27 RCTs: −0.61 mmol/L total cholesterol, −0.65 mmol/L LDL, −0.50 mmol/L triglycerides vs placebo. [5]

⚖️

Anti-Obesity / Weight Management

Modest but consistent weight reduction vs placebo across 12 RCTs — mean 1.78 kg. [6] Effects appear secondary to glucose and lipid modulation rather than direct appetite suppression. Greatest in metabolic syndrome populations. Effects build over 12+ weeks of use.

🔥

Anti-Inflammatory

Inhibits NF-κB nuclear translocation, reducing TNF-α, IL-1β and IL-6 production. [13] Reduces C-reactive protein in metabolic syndrome. Explains benefit in NAFLD, cardiovascular risk populations and conditions driven by chronic low-grade inflammation.

🦠

Gut Microbiota Modulation

Selectively inhibits gram-positive bacteria while enriching SCFA-producing species including Akkermansia muciniphila — associated with insulin sensitivity and gut barrier integrity. [14],[15] This mechanism is now considered primary for metabolic effects given berberine’s low systemic bioavailability.

💊

Cardiovascular — PCSK9 Inhibition

Inhibits PCSK9 expression, increasing hepatic LDL receptor recycling — a mechanism shared by injectable pharmaceutical evolocumab. [16] In heart failure patients, berberine 1,200 mg/day reduced mortality and improved left ventricular ejection fraction vs standard care. [17]

🧬

PCOS — Hormonal Metabolic Correction

Comparable to metformin in fasting insulin reduction, testosterone normalisation and menstrual regularity in PCOS RCTs. [8],[9] Greater LDL and triglyceride reductions than metformin in head-to-head trial. Relevant given PCOS prevalence of 10–15% of women of reproductive age.

🛡️

Antimicrobial

Broad-spectrum activity against gram-positive and gram-negative bacteria, Candida species and certain intestinal parasites. [18] Traditional gastrointestinal use in TCM and Ayurveda is pharmacologically supported — berberine reaches high luminal concentrations relative to its low systemic absorption.

🧠

Neuroprotective — Emerging Evidence

Preclinical evidence for neuroprotective activity via AMPK and anti-inflammatory pathways. [19] Preliminary human data in depression and mild cognitive impairment. Evidence is insufficient for clinical recommendations at this time. Active area of ongoing research.

Pharmacodynamics

Mechanisms of Action

Berberine is pleiotropic — it acts simultaneously on multiple molecular targets, explaining why its clinical effects span glucose, lipids, inflammation and the microbiome concurrently.

⚡

AMPK Activation — Primary Mechanism

Berberine activates AMP-activated protein kinase (AMPK), the cell’s primary energy sensor. AMPK activation increases GLUT4 translocation to cell membranes (glucose uptake), stimulates fatty acid β-oxidation, inhibits de novo cholesterol synthesis via HMG-CoA reductase suppression, and reduces hepatic gluconeogenesis. This single mechanism explains berberine’s simultaneous effects on blood glucose, LDL cholesterol, triglycerides and body fat. [20],[21]

🔬

Mitochondrial Complex I Inhibition

Berberine partially inhibits mitochondrial complex I of the electron transport chain, raising the AMP:ATP ratio. This AMP accumulation is the direct upstream trigger for AMPK activation. This mechanism is identical to metformin’s primary mode of action — explaining both comparable glycaemic efficacy in RCTs and why combining berberine with metformin or sulfonylureas significantly increases hypoglycaemia risk. [22]

🧬

PCSK9 Gene Expression Inhibition

Berberine downregulates PCSK9, a protein that degrades hepatic LDL receptors after each receptor-mediated endocytosis cycle. By suppressing PCSK9, berberine increases LDL receptor recycling and density on liver cell surfaces, accelerating clearance of circulating LDL cholesterol. This mechanism is distinct from statin HMG-CoA reductase inhibition and is the primary basis for berberine’s LDL-lowering activity. [16],[23]

🦠

Gut Microbiota Remodelling

Berberine’s paradox — low systemic bioavailability (~1–5%) yet substantial metabolic effects — is resolved by gut microbiota modulation. High luminal concentrations selectively inhibit pathogenic gram-positive bacteria and promote growth of beneficial SCFA-producing species, most notably Akkermansia muciniphila, independently associated with improved insulin sensitivity, reduced gut permeability and lower systemic inflammation. [14],[15]

🔴

NF-κB Pathway Suppression

Berberine inhibits nuclear factor kappa B (NF-κB) nuclear translocation, blocking transcription of pro-inflammatory genes including TNF-α, IL-1β, IL-6 and COX-2. This anti-inflammatory action is synergistic with AMPK activation (which independently suppresses NF-κB) and underlies berberine’s clinical effects in conditions driven by chronic low-grade inflammation — including metabolic syndrome, NAFLD, PCOS and atherosclerosis. [13]

🩸

Insulin Receptor Upregulation

Independent of AMPK activation, berberine increases insulin receptor expression and tyrosine phosphorylation on cell surfaces, improving insulin sensitivity through an additional, distinct pathway. Particularly relevant in type 2 diabetes and PCOS, where receptor downregulation driven by chronic hyperinsulinaemia is a primary pathophysiological driver of impaired peripheral glucose uptake. [24]

🏭

Hepatic Gluconeogenesis Inhibition

Berberine suppresses expression of two key gluconeogenic enzymes — phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) — reducing hepatic de novo glucose production. This mechanism contributes to fasting blood glucose reduction independently of peripheral insulin sensitisation, and is additive with AMPK-mediated and insulin receptor-mediated pathways. [25]

Clinical Applications

Clinical Indications

Ranked by strength of clinical evidence. Only indications supported by human randomised controlled trials or robust meta-analyses are listed.

🩸
Type 2 Diabetes & Insulin Resistance
Evidence Grade A · Multiple RCTs · 14-Trial Meta-Analysis
  • HbA1c reduction: −0.71% vs placebo across 14 RCTs (n=1,068); −2.0% vs baseline in 3-month head-to-head vs metformin. [1],[3]
  • Fasting blood glucose: Mean reduction of 1.03 mmol/L vs placebo in meta-analysis of 14 trials. [3]
  • Postprandial glucose: Significant reduction in 2-hour postprandial glucose at 500 mg three times daily. [1]
  • Insulin sensitivity: Improved HOMA-IR in multiple trials via insulin receptor upregulation and gut microbiota remodelling. [24]
❤️
Dyslipidaemia — LDL & Triglycerides
Evidence Grade A · 27-RCT Meta-Analysis
  • LDL cholesterol: Mean −0.65 mmol/L (−25 mg/dL) vs placebo, meta-analysis of 27 RCTs. [5]
  • Total cholesterol: Mean −0.61 mmol/L vs placebo in the same 27-trial analysis. [5]
  • Triglycerides: −0.50 mmol/L vs placebo; clinically meaningful in hypertriglyceridaemia. [5]
  • Mechanism: PCSK9 inhibition + AMPK-driven fatty acid oxidation — dual mechanism complementary to statins. [16]
🧬
Polycystic Ovarian Syndrome (PCOS)
Evidence Grade B · RCT vs Metformin · IVF Data
  • vs Metformin (Wei et al. 2012): Comparable reductions in fasting insulin, testosterone and improved menstrual regularity. [8]
  • Lipid advantage: Greater LDL and triglyceride reductions than metformin in the same PCOS trial. [8]
  • IVF outcomes: Improved IVF pregnancy rates and reduced OHSS risk in PCOS patients (An et al. 2014). [9]
  • Clinical relevance: PCOS affects 10–15% of women of reproductive age; berberine offers a non-prescription option with dual glucose and lipid benefit.
⚖️
Metabolic Syndrome, NAFLD & Weight
Evidence Grade B · Multiple RCTs
  • Weight reduction: Mean 1.78 kg greater than placebo across 12 RCTs; most pronounced in metabolic syndrome. [6]
  • Waist circumference: Significant reduction in visceral adiposity in multiple trials. [27]
  • NAFLD: Yan et al. (2015): significant liver fat reduction and ALT normalisation vs placebo. [28]
  • CRP: Significant reductions in C-reactive protein alongside glucose and lipid improvements in metabolic syndrome. [13]
Head-to-Head Analysis

Berberine vs Metformin

The most searched berberine comparison. A balanced clinical assessment of what the evidence actually demonstrates.

Key Evidence — Zhang et al. 2008, Metabolism

Comparable glycaemic efficacy in a 3-month head-to-head RCT

In 116 treatment-naïve type 2 diabetic patients, berberine 500 mg three times daily reduced HbA1c by 2.0% versus metformin’s 1.8% reduction over 3 months. Fasting blood glucose reductions were also comparable. Berberine additionally produced greater reductions in total cholesterol, triglycerides and LDL than metformin in the same cohort. [1]

Where Berberine Excels

  • Greater lipid lowering (LDL, TG) than metformin in head-to-head trial [1]
  • Available without prescription — no clinical consultation required for access
  • PCSK9 inhibition — a mechanism metformin does not share
  • Gut microbiota modulation with potential benefits beyond metabolic outcomes
  • Well tolerated when taken with food and titrated from a lower starting dose

Where Metformin Has the Advantage

  • Decades of RCT data including long-term cardiovascular outcome trials (UKPDS, DPPOS)
  • Regulatory pharmaceutical approval with standardised GMP manufacturing
  • Established dosing titration, monitoring and prescribing protocols
  • Berberine’s CYP3A4 inhibition creates more drug interactions than metformin
  • Supplement quality varies — batch-to-batch consistency not equivalent to pharmaceutical grade
Safety & Precautions

Safety, Contraindications & Drug Interactions

🚫

Absolute Contraindications

  • Pregnancy: Berberine crosses the placental barrier. Animal studies demonstrate teratogenic effects. Contraindicated throughout all trimesters. [29]
  • Breastfeeding: Berberine is detectable in breast milk. Contraindicated during lactation. [29]
  • Neonates: Berberine can displace bilirubin from albumin, increasing neonatal jaundice risk. Absolutely contraindicated. [30]
  • Hypersensitivity to berberine or any Berberis or Berberidaceae species.
⚠️

Gastrointestinal Side Effects

  • Incidence: Approximately 25–35% of users at standard doses report GI effects. [2]
  • Symptoms: Nausea, diarrhoea, abdominal cramping, constipation — often variable and unpredictable between individuals.
  • Course: Dose-dependent; typically resolve within 2–4 weeks as gut microbiota adapt to berberine’s antimicrobial activity.
  • Mitigation: Always take with food; titrate from 500 mg twice daily before increasing to three times daily; never take as a single large daily dose.

Drug Interactions — Clinically Significant

Berberine inhibits CYP3A4, CYP2D6, CYP2C9 and P-glycoprotein. This can raise plasma concentrations of co-administered drugs metabolised by these pathways to potentially toxic levels:

Drug / Class Interaction Mechanism Clinical Risk Recommendation
Metformin Additive glucose-lowering (shared mitochondrial complex I target) Hypoglycaemia Monitor blood glucose; metformin dose adjustment may be required
Cyclosporine CYP3A4 + P-gp inhibition → ↑ cyclosporine plasma levels High — avoid combination Contraindicated in transplant patients; consult transplant physician
Warfarin CYP2C9 inhibition → ↑ warfarin exposure and anticoagulant effect High — monitor INR closely Monitor INR at initiation and after any dose change
Statins (simvastatin, atorvastatin) CYP3A4 inhibition → ↑ statin plasma concentrations Myopathy risk Monitor for muscle symptoms; pravastatin (non-CYP3A4) is safer option
Sulfonylureas Additive hypoglycaemic effect Hypoglycaemia Monitor blood glucose; sulfonylurea dose reduction may be needed
Macrolide antibiotics Additive CYP3A4 inhibition during antibiotic course Low–Moderate Temporary caution during course; resume normal monitoring after completion
Medical disclaimer: This list is not exhaustive. Any person taking prescription medications — particularly narrow-therapeutic-index drugs — should consult a qualified healthcare provider before initiating berberine. This page is for educational reference only and does not constitute medical advice, diagnosis or treatment guidance.
Frequently Asked Questions

Berberine FAQ

What does berberine do in the body?
Berberine activates AMP-activated protein kinase (AMPK), the body’s primary metabolic energy sensor. This increases cellular glucose uptake, fatty acid oxidation and suppresses cholesterol synthesis. Berberine additionally inhibits PCSK9 (clearing LDL from circulation), remodels gut microbiota composition, suppresses NF-κB inflammatory signalling, and inhibits hepatic gluconeogenesis. This multi-pathway activity explains its documented concurrent effects across blood glucose, cholesterol, inflammation and body weight.
What is the correct dosage of berberine?
The evidence-based dose used in most clinical trials is 500 mg of berberine HCl taken 2–3 times daily with meals, totalling 1,000–1,500 mg per day. New users should start at 500 mg twice daily for 1–2 weeks before increasing to three times daily to allow gut microbiota to adapt and minimise gastrointestinal side effects.
Is berberine as effective as metformin for blood sugar?
In the landmark 2008 Zhang et al. RCT published in Metabolism, berberine 500 mg three times daily reduced HbA1c by 2.0% compared to metformin’s 1.8% reduction over 3 months in treatment-naïve type 2 diabetics — with berberine additionally producing greater LDL and triglyceride reductions. However, berberine is not an approved pharmaceutical and metformin’s evidence base includes decades of RCTs plus long-term cardiovascular outcome trials that berberine lacks. Both inhibit mitochondrial complex I and activate AMPK by the same mechanism.
What are the main side effects of berberine?
The most common side effects are gastrointestinal — nausea, diarrhoea, cramping and constipation — reported in approximately 25–35% of users at standard doses. These are dose-dependent and typically resolve within 2–4 weeks as the gut microbiota adapts. Taking berberine with food and starting at a lower dose (500 mg twice daily) significantly reduces these effects. Berberine also inhibits CYP3A4, CYP2D6 and P-glycoprotein, creating clinically significant drug interactions. It is contraindicated in pregnancy and breastfeeding.
Can berberine interact with medications?
Yes — drug interactions are the most important safety consideration with berberine. It inhibits CYP3A4, CYP2D6, CYP2C9 and P-glycoprotein, which can raise plasma concentrations of co-administered drugs to potentially toxic levels. The most clinically significant interactions are with: metformin and sulfonylureas (additive hypoglycaemia), cyclosporine (potentially toxic plasma levels — avoid), warfarin (INR instability — monitor closely), and simvastatin or atorvastatin (myopathy risk). Always consult a healthcare provider before combining berberine with any prescription medication.
How long does berberine take to work?
Clinical trials show measurable reductions in fasting blood glucose within 2–4 weeks and significant HbA1c reductions at 8–12 weeks of consistent daily use at 1,000–1,500 mg/day. Lipid changes are typically measurable at 8–12 weeks. Weight effects, where present, are most apparent at 12+ weeks. Individual response varies based on baseline metabolic status, dietary pattern, dosing consistency and gut microbiota composition.
Should I take berberine with or without food?
Always with food — and this is not optional. Food slows gastric transit, significantly prolonging berberine’s contact time with the intestinal mucosa and gut microbiota, improving net metabolic activity despite low systemic bioavailability. It also substantially reduces gastrointestinal side effects. The clinical dose of “500 mg three times daily” in all trials refers to administration with each main meal.
Is berberine safe long-term?
Clinical trials up to 24 months have not identified significant hepatotoxicity, nephrotoxicity or haematological adverse effects at standard doses (1,000–1,500 mg/day). However, long-term safety data beyond 2 years is limited. Berberine’s CYP enzyme inhibition creates ongoing drug interaction risk in individuals on multiple medications. Long-term use is contraindicated throughout pregnancy and lactation. Individuals on multiple prescription medications should use berberine only under medical supervision.
Primary Literature

Bibliography

↑ 1. Zhang Y, Li X, Zou D, et al. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. J Clin Endocrinol Metab. 2008;93(7):2559–65. PubMed PMID:18397984 →
↑ 2. Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism. 2008;57(5):712–7. PubMed PMID:18442638 →
↑ 3. Liang Y, Xu X, Yin M, et al. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2019;2019:7212971. PubMed PMID:31214255 →
↑ 4. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10(12):1344–51. PubMed PMID:15531889 →
↑ 5. Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. Evid Based Complement Alternat Med. 2012;2012:591654. PubMed PMID:23118793 →
↑ 6. Hu Y, Ehli EA, Kittelsrud J, et al. Lipid-lowering effect of berberine in human subjects and rats. Phytomedicine. 2012;19(10):861–7. PubMed PMID:22739410 →
↑ 7. Pérez-Rubio KG, González-Ortiz M, Martínez-Abundis E, et al. Effect of berberine administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab Syndr Relat Disord. 2013;11(5):366–9. PubMed PMID:23808999 →
↑ 8. Wei W, Zhao H, Wang A, et al. A clinical study on the short-term effect of berberine in comparison to metformin on the metabolic characteristics of women with polycystic ovary syndrome. Eur J Endocrinol. 2012;166(1):99–105. PubMed PMID:22049079 →
↑ 9. An Y, Sun Z, Zhang Y, et al. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425–31. PubMed PMID:23869668 →
↑ 10. Liu LZ, Cheung SC, Lan LL, et al. Berberine modulates insulin signaling transduction in insulin-resistant cells. Mol Cell Endocrinol. 2010;317(1–2):148–53. PubMed PMID:19941933 →
↑ 11. Yin J, Ye J, Jia W. Effects and mechanisms of berberine in diabetes treatment. Acta Pharmaceutica Sinica B. 2012;2(4):327–34.
↑ 12. Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol. 2015;161:69–81. PubMed PMID:25498346 →
↑ 13. Zhu X, Bian H, Wang L, et al. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway. Free Radic Biol Med. 2019;141:192–204. PubMed PMID:31279895 →
↑ 14. Tian Y, Cai J, Gui W, et al. Berberine directly affects the gut microbiota to promote intestinal farnesoid X receptor signalling. Drug Metab Dispos. 2019;47(2):86–93. PubMed PMID:30530827 →
↑ 15. Zhang X, Zhao Y, Zhang M, et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7(8):e42529. PubMed PMID:22880019 →
↑ 16. Li H, Dong B, Park SW, et al. Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypolipidemic compound berberine. J Biol Chem. 2009;284(40):28885–95. PubMed PMID:19687010 →
↑ 17. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2003;92(2):173–6. PubMed PMID:12860219 →
↑ 18. Chu M, Zhang MB, Liu YC, et al. Role of berberine in the treatment of methicillin-resistant Staphylococcus aureus infections. Sci Rep. 2016;6:24748. PubMed PMID:27102561 →
↑ 19. Bhutada P, Mundhada Y, Bansod K, et al. Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav Brain Res. 2011;220(1):30–41. PubMed PMID:21238489 →
↑ 20. Lee YS, Kim WS, Kim KH, et al. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes. 2006;55(8):2256–64. PubMed PMID:16873688 →
↑ 21. Turner N, Li JY, Gosby A, et al. Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I. Diabetes. 2008;57(5):1414–8. PubMed PMID:18316364 →
↑ 22. Hawley SA, Ross FA, Chevtzoff C, et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010;11(6):554–65. PubMed PMID:20519126 →
↑ 23. Abidi P, Zhou Y, Jiang JD, Liu J. Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine. Arterioscler Thromb Vasc Biol. 2005;25(12):2577–9. PubMed PMID:16224047 →
↑ 24. Wang ZS, Feng ZB, Wu GF, et al. The use of berberine in the treatment of type 2 diabetes in China from 1987 to 2014: a systematic review and meta-analysis. J Diabetes Investig. 2017;8(2):195–205. PubMed PMID:27381202 →
↑ 25. Kong W, Wei J, Zuo ZY, et al. Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metabolism. 2008;57(8):1029–37. PubMed PMID:18640380 →
↑ 26. Li L, Li C, Pan P, et al. A single arm pilot study of effects of berberine on the menstrual pattern, ovulation rate, hormonal and metabolic profiles in anovulatory Chinese women with PCOS. PLoS One. 2015;10(12):e0144072. PubMed PMID:26641959 →
↑ 27. Cicero AF, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci. 2012;8(5):907–17. PubMed PMID:23185199 →
↑ 28. Yan HM, Xia MF, Wang Y, et al. Efficacy of berberine in patients with non-alcoholic fatty liver disease. PLoS One. 2015;10(8):e0134172. PubMed PMID:26252777 →
↑ 29. Vutyavanich T, Krasaesin S, Worapitaksanond S. Berberine: review of pharmacology and safety. J Med Assoc Thai. 2009;92 Suppl 7:S202–6.
↑ 30. Chan E. Displacement of bilirubin from albumin by berberine. Biol Neonate. 1993;63(4):201–8. PubMed PMID:8513023 →

Additional Reference Literature

Pirillo A, Catapano AL. Berberine, a plant alkaloid with lipid-and glucose-lowering properties: from in vitro evidence to clinical studies. Atherosclerosis. 2015;243(2):449–61. PubMed PMID:26520899 →
Imenshahidi M, Hosseinzadeh H. Berberis vulgaris and berberine: an update review. Phytother Res. 2016;30(11):1745–64. PubMed PMID:27528198 →
Chen C, Zhang Y, Huang C. Berberine inhibits PTP1B activity and mimics insulin action. Biochem Biophys Res Commun. 2010;397(3):543–7. PubMed PMID:20515652 →
Ruan H, Li Y, Ling W, et al. Berberine and its derivatives: a patent review (2009–2020). Expert Opin Ther Pat. 2021;31(8):745–65. PubMed PMID:33745406 →